scispace - formally typeset
Search or ask a question
Institution

University of Paris

EducationParis, France
About: University of Paris is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Medicine. The organization has 102426 authors who have published 174180 publications receiving 5041753 citations. The organization is also known as: Sorbonne.


Papers
More filters
Journal ArticleDOI
Gerald B. Appel1, Gabriel Contreras2, Mary Anne Dooley3, Ellen M. Ginzler4, David A. Isenberg5, David Jayne6, Lei Shi Li, Eduardo Mysler, Jorge Sánchez-Guerrero, Neil Solomons, David Wofsy7, Carlos Abud, Sharon G. Adler8, Graciela S. Alarcón9, Elisa N. Albuquerque10, Fernando Almeida, Alejandro Alvarellos, Gerald B. Appel1, Hilario Avila11, Cornelia Blume12, Ioannis Boletis, Alain Bonnardeaux, Alan Braun, Jill P. Buyon13, Ricard Cervera14, Nan Chen15, Shun-Le Chen15, António Gomes Da Costa16, Razeen Davids17, David D'Cruz18, Enrique de Ramón, Atul Deodhar19, Andrea Doria20, Bertrand Dussol, Paul Emery21, Justus Fiechtner, Jürgen Floege, Hilda Fragoso-Loyo, Richard Furie22, Rozina Ghazalli23, Cybele Ghossein23, Gary S. Gilkeson24, EM Ginzler25, Caroline Gordon8, Jennifer M. Grossman8, Jieruo Gu26, Loïc Guillevin, Pierre Yves Hatron27, Gisela Herrera28, Falk Hiepe28, Frédéric Houssiau, Osvaldo Hübscher, Claudia Hura29, Joshua Kaplan30, Gianna Mastroianni Kirsztajn30, Emese Kiss31, Ghazali Ahmad Kutty, Maurice Laville, Maria Lazaro, Oliver Lenz2, Leishi Li32, Liz Lightstone33, Sam Lim34, Michel Malaise35, Susan Manzi35, Juan Carlos Marcos, Olivier Meyer36, Pablo Monge37, Saraladev Naicker37, Nathaniel Neal38, Michael Neuwelt39, Kathy Nicholls40, Nancy J. Olsen40, José Ordi-Ros41, Barbara E. Ostrov42, Manuel Pestana43, Michelle Petri44, G. Pokorny44, Jacques Pourrat15, Jiaqi Qian15, Jai Radhakrishnan1, Brad H. Rovin, Julio Sanchez Roman, Joseph C. Shanahan45, William Shergy, Fotini Skopouli, Alberto Spindler46, Christopher Striebich47, Robert Sundel48, Charles R. Swanepoel48, Yen Tan Si49, Guillermo Tate, Vladimír Tesaŕ37, Mohamed Tikly37, Haiyan Wang, Rosnawati Yahya50, Xueqing Yu26, Fengchun Zhang50, Diana Zoruba 
Columbia University1, University of Miami2, University of North Carolina at Chapel Hill3, SUNY Downstate Medical Center4, University College London5, Cambridge University Hospitals NHS Foundation Trust6, University of California, San Francisco7, University of California, Los Angeles8, University of Alabama at Birmingham9, Rio de Janeiro State University10, University of Guadalajara11, University of Düsseldorf12, New York University13, University of Barcelona14, Shanghai Jiao Tong University15, University of Lisbon16, Stellenbosch University17, Guy's and St Thomas' NHS Foundation Trust18, Oregon Health & Science University19, University of Padua20, University of Leeds21, North Shore-LIJ Health System22, Northwestern University23, Medical University of South Carolina24, University of Birmingham25, Sun Yat-sen University26, Lille University of Science and Technology27, Charité28, Rutgers University29, Federal University of São Paulo30, University of Debrecen31, Imperial College London32, Emory University33, University of Liège34, University of Pittsburgh35, University of Paris36, University of the Witwatersrand37, California State University, Long Beach38, Royal Melbourne Hospital39, University of Texas Southwestern Medical Center40, Autonomous University of Barcelona41, Pennsylvania State University42, Johns Hopkins University43, University of Szeged44, Duke University45, University of Colorado Denver46, Harvard University47, University of Cape Town48, University of Malaya49, Peking Union Medical College50
TL;DR: Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Abstract: Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.

909 citations

Journal ArticleDOI
TL;DR: It is demonstrated that the risk of death of toxic epidermal necrolysis patients can be accurately predicted by the toxic epidescent severity-of-illness score, and the Simplified Acute Physiology Score and burn score appear to be less adequate.

908 citations

Journal ArticleDOI
TL;DR: The EROS-2 project was designed to test the hypothesis that massive compact halo objects (the so-called ''machos'') could be a major component of the dark matter halo of the Milky Way galaxy.
Abstract: The EROS-2 project was designed to test the hypothesis that massive compact halo objects (the so-called ''machos'') could be a major component of the dark matter halo of the Milky Way galaxy. To this end, EROS-2 monitored millions of stars in the Magellanic clouds for microlensing events caused by such objects. (abridged)

908 citations

Journal ArticleDOI
TL;DR: The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment.
Abstract: A preceding article described the clinical features of Parkinson's disease dementia (PD-D) and proposed clinical diagnostic criteria for "probable" and "possible" PD-D. The main focus of this article is to operationalize the diagnosis of PD-D and to propose practical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time-consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD-D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD-D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence-based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies.

907 citations

Journal ArticleDOI
TL;DR: The heart-rate profile during exercise and recovery is a predictor of sudden death among apparently healthy persons, with a moderate but significantly increased risk of death from any cause but not of nonsudden death from myocardial infarction.
Abstract: background Changes in heart rate during exercise and recovery from exercise are mediated by the balance between sympathetic and vagal activity. Since alterations in the neural control of cardiac function contribute to the risk of sudden death, we tested the hypothesis that among apparently healthy persons, sudden death is more likely to occur in the presence of abnormal heart-rate profiles during exercise and recovery. methods A total of 5713 asymptomatic working men (between the ages of 42 and 53 years), none of whom had clinically detectable cardiovascular disease, underwent standardized graded exercise testing between 1967 and 1972. We examined data on the subjects’ resting heart rates, the increase in rate from the resting level to the peak exercise level, and the decrease in rate from the peak exercise level to the level one minute after the termination of exercise. results During a 23-year follow-up period, 81 subjects died suddenly. The risk of sudden death from myocardial infarction was increased in subjects with a resting heart rate that was more than 75 beats per minute (relative risk, 3.92; 95 percent confidence interval, 1.91 to 8.00); in subjects with an increase in heart rate during exercise that was less than 89 beats per minute (relative risk, 6.18; 95 percent confidence interval, 2.37 to 16.11); and in subjects with a decrease in heart rate of less than 25 beats per minute after the termination of exercise (relative risk, 2.20; 95 percent confidence interval, 1.02 to 4.74). After adjustment for potential confounding variables, these three factors remained strongly associated with an increased risk of sudden death, with a moderate but significantly increased risk of death from any cause but not of nonsudden death from myocardial infarction. conclusions The heart-rate profile during exercise and recovery is a predictor of sudden death.

904 citations


Authors

Showing all 102613 results

NameH-indexPapersCitations
Guido Kroemer2361404246571
David H. Weinberg183700171424
Paul M. Thompson1832271146736
Chris Sander178713233287
Sophie Henrot-Versille171957157040
Richard H. Friend1691182140032
George P. Chrousos1691612120752
Mika Kivimäki1661515141468
Martin Karplus163831138492
William J. Sandborn1621317108564
Darien Wood1602174136596
Monique M.B. Breteler15954693762
Paul Emery1581314121293
Wolfgang Wagner1562342123391
Joao Seixas1531538115070
Network Information
Related Institutions (5)
Centre national de la recherche scientifique
382.4K papers, 13.6M citations

95% related

École Normale Supérieure
99.4K papers, 3M citations

94% related

Imperial College London
209.1K papers, 9.3M citations

93% related

Sapienza University of Rome
155.4K papers, 4.3M citations

93% related

University of Groningen
69.1K papers, 2.9M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202376
2022602
202116,433
202015,008
201911,047
20189,091